Pancreatic Cancer News and Research RSS Feed - Pancreatic Cancer News and Research

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.
CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

CanTx, Novogen name two key CMOs to manufacture clinical batches of anti-cancer drug Cantrixil

Oncology drug developer, CanTx Inc., and its parent company, Novogen Ltd., today announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil. [More]
Cedars-Sinai investigators developing novel treatment for locally advanced pancreatic cancer

Cedars-Sinai investigators developing novel treatment for locally advanced pancreatic cancer

Investigators at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute are developing a novel, multistep investigational treatment for one of the most complex and difficult-to-treat forms of the disease, locally advanced pancreatic cancer. [More]
Saltier intravenous drip reduces overall rate of complications by 25% after Whipple surgery

Saltier intravenous drip reduces overall rate of complications by 25% after Whipple surgery

Adequate hydration via a saline drip is essential during surgery, but recent reports suggest that getting the balance of salt and water just right could have an important impact on patient recovery. [More]
Oncolytics completes patient enrollment in phase II metastatic pancreatic cancer study

Oncolytics completes patient enrollment in phase II metastatic pancreatic cancer study

Oncolytics Biotech Inc. today announced completion of patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plus REOLYSIN versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045). [More]
Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL). [More]

Researchers receive over $1M to study molecular foundations of pancreatic cancer

Alexandros Tzatsos, M.D., Ph.D., assistant professor of anatomy and regenerative biology at the George Washington University School of Medicine and Health Sciences, was awarded over one million dollars in grants from the National Institutes of Health to study the molecular foundations of pancreatic cancer. [More]
Extract of Chinese herb thunder god vine suppresses pancreatic cancer cell

Extract of Chinese herb thunder god vine suppresses pancreatic cancer cell

A diagnosis of pancreatic cancer—the fourth most common cause of cancer death in the U.S.—can be devastating. Due in part to aggressive cell replication and tumor growth, pancreatic cancer progresses quickly and has a low five-year survival rate (less than 5 percent). [More]
Researchers identify new protein as possible therapeutic target for pancreatic cancer

Researchers identify new protein as possible therapeutic target for pancreatic cancer

Researchers from IMIM (Hospital del Mar Medical Research Institute) have identified a new protein, galectin-1, as a possible therapeutic target for pancreatic cancer. [More]
Some cancer patients with aggressive tumors may benefit from anti-inflammatory drugs

Some cancer patients with aggressive tumors may benefit from anti-inflammatory drugs

New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis. [More]
Use of low-dose aspirin associated with cutting risk of pancreatic cancer in half

Use of low-dose aspirin associated with cutting risk of pancreatic cancer in half

The longer a person took low-dose aspirin, the lower his or her risk for developing pancreatic cancer, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. [More]
Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Adding the novel MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
Clusters of protein linked to cancer warp cell membranes

Clusters of protein linked to cancer warp cell membranes

Supercomputer simulations have shown that clusters of a protein linked to cancer warp cell membranes, according to scientists at The University of Texas Health Science Center at Houston (UTHealth) Medical School. [More]
Yap1 oncogene drives recurrence and progression of pancreatic cancer

Yap1 oncogene drives recurrence and progression of pancreatic cancer

Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell. [More]
New vaccine reprograms pancreatic tumors and makes them vulnerable to immunotherapy

New vaccine reprograms pancreatic tumors and makes them vulnerable to immunotherapy

Researchers at the Johns Hopkins Kimmel Cancer Center have developed and tested a vaccine that triggered the growth of immune cell nodules within pancreatic tumors, essentially reprogramming these intractable cancers and potentially making them vulnerable to immune-based therapies. [More]
Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

Medical investigators at the Virginia G. Piper Cancer Center at Scottsdale Healthcare are studying a new cancer immunotherapy to see if it can successfully help patients with advanced pancreatic cancer. [More]
Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer. [More]
Blood oxygen sensor attached to endoscope identifies pancreatic cancer

Blood oxygen sensor attached to endoscope identifies pancreatic cancer

An optical blood oxygen sensor attached to an endoscope is able to identify pancreatic cancer in patients via a simple lendoscopic procedure, according to researchers at Mayo Clinic in Florida. [More]
New drug shows promising results in patients with advanced pancreatic cancer

New drug shows promising results in patients with advanced pancreatic cancer

A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute, showed that a new drug called MM-398, given in combination with 5-flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously-treated pancreatic cancer. [More]
Rice, MD Anderson researchers refine technique for attacking hard-to-reach tumors

Rice, MD Anderson researchers refine technique for attacking hard-to-reach tumors

Short, customized carbon nanotubes have the potential to deliver drugs to pancreatic cancer cells and destroy them from within, according to researchers at Rice University and the University of Texas MD Anderson Cancer Center. [More]
Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Advanced Cancer Therapeutics, a privately held company dedicated to bringing new anti-cancer therapies to market, announced today (June 4) that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials. [More]